# TALAPRO-1 (NCT03148795)

> A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: talazoparib
- Indication: metastatic castration-resistant prostate cancer with DNA repair alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03148795
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Prostate Cancer
- Interventions: Talazoparib
- Enrollment: 128
- Primary outcome: Best Objective Response Rate (ORR)

## Indexed commentary on TALAPRO-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X
- 6 YouTube videos
- 6 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=talapro-1-nct03148795

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03148795", "email": "<work email>"}; the inbox owner confirms by the emailed link.